Treatment Clinical Trials for Uterine Sarcoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for uterine sarcoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-14 of 14
  • Medroxyprogesterone Acetate with or without Entinostat before Surgery in Treating Patients with Endometrioid Endometrial Cancer

    This randomized phase II trial studies how well medroxyprogesterone acetate with or without entinostat before surgery works in treating patients with endometrioid endometrial cancer. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Given medroxyprogesterone acetate with or without entinostat may work better in treating patients with endometrioid endometrial cancer.
    Location: 202 locations

  • Nivolumab in Treating Patients with Metastatic or Recurrent Uterine Cancer

    This phase II trial studies how well nivolumab works in treating patients with uterine cancer that has spread to other places in the body or come back after a period of improvement. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
    Location: 6 locations

  • Nivolumab Alone or in Combination with Ipilimumab in Treating Patients with Advanced Uterine Leiomyosarcoma

    This phase II trial studies how well nivolumab alone or in combination with ipilimumab works in treating patients with uterine cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

    This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSFencoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Interferon Gamma-1b and Nivolumab in Treating Patients with Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of interferon gamma-1b when given together with nivolumab and to see how well they work in treating patients with solid tumors that have spread from the primary site to other places in the body. Biological therapies, such as interferon gamma-1b, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Giving interferon gamma-1b and nivolumab may work better in treating patients with metastatic solid tumors.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • Phase 1 / 2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

    The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
    Location: 2 locations

  • Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

    This pilot clinical trial studies gemcitabine hydrochloride, docetaxel, and radiation therapy in treating patients with uterine sarcoma that has been removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy with radiation therapy may kill any tumor cells that remain after surgery.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well it works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Proton Beam Radiation Therapy in Treating Patients with Uterine or Cervical Cancer with Regional Lymph Node Metastases

    This pilot clinical trial studies proton beam radiation therapy in treating patients with uterine or cervical cancer that has spread to regional lymph nodes (metastases). Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
    Location: Massachusetts General Hospital, Charlestown, Massachusetts

  • Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

    This pilot clinical trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.
    Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York

  • HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma

    The purpose of this study is to obtain blood from sarcoma patients to see if researchers can make cells that are able to fight and kill sarcoma cells. If researchers are able to do this, these T cells may be offered back to the patient in the future if the patient is eligible to participate in a treatment research study using these cells. Should this occur, as separate consent will be obtained that will provide much more information about the risks and potential benefits of this treatment. The purpose of this study is also to find the largest safe dose of chimeric T cells, to learn what the side effects are, and to see whether this therapy might help patients with sarcoma.
    Location: Baylor College of Medicine / Dan L Duncan Comprehensive Cancer Center, Houston, Texas

  • Mifepristone in Treating Patients With Cancer

    The purpose of this compassionate use study is to see if mifepristone prevents worsening of patients' cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. Mifepristone has not been approved by the Food and Drug Administration for use in the treatment of cancer. However, previous work has indicated that mifepristone may be useful due to how it works.
    Location: University of New Mexico Cancer Center, Albuquerque, New Mexico

  • Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma

    This partially randomized phase I / II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 359 locations

  • Ultrasound Hyperthermia Therapy After Implant Radiation Therapy in Treating Patients With Urinary Tract Cancer, Gynecologic Cancer, or Head and Neck Cancer

    This pilot clinical trial is studying ultrasound hyperthermia therapy to see how well it works after implant radiation therapy in treating patients with urinary tract cancer, gynecologic cancer, or head and neck cancer. Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Ultrasound energy may be able to kill tumor cells by heating up the tumor cells without affecting the surrounding tissue. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving ultrasound hyperthermia therapy after implant radiation therapy may kill more tumor cells.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California